Paul Tudor Jones's NVCR Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 284,645 shares of NovoCure Limited (NVCR) worth $3.68 M, representing 0.01% of the portfolio. First purchased in 2016-Q2, this long-term strategic position has been held for 30 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in NVCR, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 354,216 shares. Largest reduction occurred in Q4 2025, reducing 321,425 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's NovoCure Limited (NVCR) Holding Value Over Time
Track share changes against reported price movement
Quarterly NovoCure Limited (NVCR) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -321,425 | Reduce 53.03% | 284,645 | $12.93 |
| Q3 2025 | +354,216 | Add 140.64% | 606,070 | $12.92 |
| Q2 2025 | +135,436 | Add 116.34% | 251,854 | $17.80 |
| Q1 2025 | +116,418 | New Buy | 116,418 | $17.82 |
| Q4 2024 | -78,752 | Sold Out | 0 | $0.00 |
| Q3 2024 | -303,830 | Reduce 79.42% | 78,752 | $15.63 |
| Q2 2024 | +17,161 | Add 4.70% | 382,582 | $17.13 |
| Q1 2024 | +181,062 | Add 98.21% | 365,421 | $15.63 |
| Q4 2023 | +100,140 | Add 118.90% | 184,359 | $14.93 |
| Q3 2023 | +6,270 | Add 8.04% | 84,219 | $16.15 |
| Q2 2023 | +14,717 | Add 23.27% | 77,949 | $41.50 |
| Q1 2023 | +36,377 | Add 135.46% | 63,232 | $0.06 |
| Q4 2022 | +26,855 | New Buy | 26,855 | $0.07 |
| Q3 2022 | -42,073 | Sold Out | 0 | $0.00 |
| Q2 2022 | +42,073 | New Buy | 42,073 | $69.50 |
| Q1 2022 | -3,531 | Sold Out | 0 | $0.00 |
| Q4 2021 | +3,531 | New Buy | 3,531 | $75.05 |
| Q3 2021 | -5,298 | Sold Out | 0 | $0.00 |
| Q2 2021 | +5,298 | New Buy | 5,298 | $221.78 |
| Q1 2021 | -15,472 | Sold Out | 0 | $0.00 |
| Q4 2020 | +15,472 | New Buy | 15,472 | $173.02 |
| Q3 2020 | -34,795 | Sold Out | 0 | $0.00 |
| Q2 2020 | +31,266 | Add 885.97% | 34,795 | $59.29 |
| Q1 2020 | -5,924 | Reduce 62.67% | 3,529 | $67.44 |
| Q4 2019 | +9,453 | New Buy | 9,453 | $84.31 |
| Q3 2019 | -30,096 | Sold Out | 0 | $0.00 |
| Q2 2019 | -18,374 | Reduce 37.91% | 30,096 | $63.23 |
| Q1 2019 | +48,470 | New Buy | 48,470 | $48.17 |
| Q3 2016 | -16,700 | Sold Out | 0 | $0.00 |
| Q2 2016 | +16,700 | New Buy | 16,700 | $11.68 |
Paul Tudor Jones's NovoCure Limited Investment FAQs
Paul Tudor Jones first purchased NovoCure Limited (NVCR) in Q2 2016, acquiring 16,700 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held NovoCure Limited (NVCR) for 30 quarters since Q2 2016.
Paul Tudor Jones's largest addition to NovoCure Limited (NVCR) was in Q3 2025, adding 606,070 shares worth $7.83 M.
According to the latest 13F filing for Q4 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 284,645 shares of NovoCure Limited (NVCR), valued at approximately $3.68 M.
As of the Q4 2025 filing, NovoCure Limited (NVCR) represents approximately 0.01% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in NovoCure Limited (NVCR) was 606,070 shares, as reported at the end of Q3 2025.